Navigation Links
GlaxoSmithKline Presents Innovative Neuroscience Pipeline
Date:12/13/2007

etabolic-related effects, such as weight gain and blood lipid increases, which are common side effects of antipsychotic treatments. In one study, patients receiving 60mg daily of '812 experienced a decrease of 1.0kg in body weight, which was a statistically significant change compared to patients receiving placebo or olanzapine, whose body weight increased by 0.9kg and 2.2kg respectively. In addition, patients receiving '812 did not show an increase in triglycerides or cholesterol levels.

The development program for '812 continues with phase IIb trials, which are expected to demonstrate benefits versus two commonly used treatments for schizophrenia. These trials are expected to start in 2008.

742457 - A novel treatment to delay the symptoms of Alzheimer's disease:

Alzheimer's disease is a devastating neurological condition, with significant consequences on the quality of life for sufferers and their care givers. GSK has a broad program of research ongoing in Alzheimer's disease, including 742457, a novel treatment that selectively targets the 5HT6 receptors concentrated within the brain. These receptors are associated with learning and memory. Currently available treatments, such as cholinesterase inhibitors, are not brain specific and alter the cholinergic system throughout the body leading to possible side effects, particularly gastrointestinal side effects.

Results from a phase II placebo-controlled dose-ranging study in 371 patients demonstrated that over a 24-week treatment period, patients receiving 35mg doses of '457 showed statistically significant improvements in global function compared to placebo as measured by the CIBIC+. The CIBIC+ is a clinician-rated scale which assesses global improvement, including input from patients' care givers. All doses of '457 appeared generally well tolerated, with a low overall incidence of adverse events.

Another phase II trial comparing 15-35mg of '457, and 5-10mg of donepezil, a commonly
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
11. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been ... business is showing its latest designs of wedding dresses and ... the company’s CEO, all the fresh new products are designed ... up to 80% off. All the clothes from LunaDress follow ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the ... created for kids with cancer. The Chemo Duck App, available on ... with enjoyable games to help children of all ages living with ... to keep kids entertained, educated and at ease while waiting for ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... may be spurring unrealistic expectations, study suggests , , WEDNESDAY, ... students are far likelier than those in the 1970s ... new research shows. , They,re also much more likely ... -- even though other research shows that today,s students ...
... according to Millennium,Research Group, WALTHAM, Mass., Nov. ... Markets for Biopsy Devices 2009 report, the,popularity of ... (GI) and breast biopsy procedures performed through 2013., ... for,visualizing tissue at the cellular level has decreased ...
... Covenant House International is,releasing its First Annual Report Card on ... their future. America,s kids in crisis will be,the focus of ... 20, 5:30 pm, in Times Square., "Over 750,000 young ... every year. We were able to help 70,387 homeless youth ...
... on Wireless ... Identification in Milan, HATBORO, Pa., Nov. 12 ... mobility and advanced,wireless asset tracking solutions for the healthcare and commercial,industries, ... predictive value of identification technology at the ID,WORLD International Congress, to ...
... New Survey Indicates that a Patient,s or Loved One,s Hearing ... to Inefficiency and ... Hearing loss among those,who require the assistance of a caregiver ... providing care, according to a new survey,released by Songbird Hearing, ...
... XR provides rapid and significant improvements in, ... Early onset of effect may help with school ... academic productivity for children with ADHD, EAST HANOVER, ... (FDA) has approved a 30-minute onset of action for,Focalin(R) ...
Cached Medicine News:Health News:U.S. Teens Brimming With Self-Esteem 2Health News:U.S. Teens Brimming With Self-Esteem 3Health News:U.S. Teens Brimming With Self-Esteem 4Health News:Advanced Imaging Technologies to Limit Breast and GI Biopsy Procedures 2Health News:Plight of Homeless Youth Will be Focus of Nov. 20 Times Square Vigil 2Health News:Plight of Homeless Youth Will be Focus of Nov. 20 Times Square Vigil 3Health News:InfoLogix CEO to Address Hidden Value of ID Technology at International Conference 2Health News:InfoLogix CEO to Address Hidden Value of ID Technology at International Conference 3Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 2Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 3Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 4Health News:US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period 2Health News:US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period 3Health News:US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period 4Health News:US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period 5Health News:US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period 6Health News:US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period 7
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... March 2, 2011 BioDelivery Sciences ... the positive outcome of a pre-Investigational New Drug ... Administration (FDA) on the development program for BEMA ... development program discussed is based on pharmacokinetic and ...
... MALVERN, Pa., March 2, 2011 Auxilium Pharmaceuticals, Inc. ... management will participate in the Cowen and Company 31st ... The Boston Marriott Copley Place.  Mr. Jim Fickenscher, Chief ... the Company and its product pipeline at 8:45 a.m. ...
Cached Medicine Technology:BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting 2BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting 3Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 3
For canalicular laceration involving external 2/3 of one canaliculus. Medical grade silicone. Box of 3, sterile. Note: For safe and proper insertion of the punctum plug above, we recommend the use of...
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
For proper plug sizing....
Contour Design Eyelid Implants....
Medicine Products: